Myasthenia Gravis: Disease, Diagnosis and Management (Developments in Immunology) - Softcover

Softcover

ISBN 10: 0443366470 ISBN 13: 9780443366475

Publisher: Academic Press, 2025

Synopsis

Myasthenia Gravis: Disease, Diagnosis and Management is a comprehensive resource that explores recent advancements in diagnosing and treating Myasthenia Gravis, a rare autoimmune disease affecting the neuromuscular junction. With contributions from global experts, this book addresses the increasing prevalence of Myasthenia Gravis, reflecting the latest in diagnostic techniques and novel therapies such as complement inhibitors and FcRn antagonists. It aims to support healthcare professionals in delivering optimal care through evidence-based insights and patient-centered approaches. The book is divided into several chapters, beginning with an overview of the pathogenesis and immunoregulatory defects in Myasthenia Gravis. Subsequent chapters cover diagnostic methods, non-immunosuppressive treatments, and biological therapies targeting the immune system. Key topics include the role of intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) in severe exacerbations, thymectomy, molecular mechanisms, and the potential of hematopoietic stem cell transplants. The book also delves into precision medicine, AI applications, clinical trial considerations, and novel therapeutics like anti-FcRn antibodies. Management strategies for ocular Myasthenia Gravis, and a holistic view of living with the disease are also discussed. Myasthenia Gravis: Disease, Diagnosis and Management is invaluable for healthcare providers, physicians, immunologists, ophthalmologists, rheumatologists, physical therapists, pharmacists, and translators. It offers a modern guide to understanding and managing Myasthenia Gravis, integrating clinical expertise with the latest research to improve patient outcomes.

• Explores pathogenesis, diagnosis, and treatment options for Myasthenia Gravis, providing a complete understanding of the disease
• Highlights cutting-edge therapies like complement inhibitors and FcRn antagonists for improved patient outcomes
• Ensures authoritative and up-to-date information contributed by global experts
• Offers evidence-based strategies for healthcare professionals to optimize Myasthenia Gravis management
• Integrates clinical expertise with patient-centered care for a well-rounded perspective on disease management

About this title

About the Authors

Dr. Bhupendra Gopalbhai Prajapati is Professor (Research Cadre) at Parul Institute of Pharmacy, Parul University, Gujarat, India, and serves as Adjunct Professor in the Department of Industrial Pharmacy at Silpakorn University, Thailand. His academic, research, and industry expertise focuses on lipid‑based formulations, nano‑ and microparticulate drug delivery systems, and strategies to enhance drug bioavailability. Dr. Prajapati has received several academic and professional honors recognizing excellence in teaching and research. He has made substantial scholarly contributions through research and review publications, book chapters, and edited volumes in pharmaceutical sciences. Actively engaged in postgraduate and doctoral mentoring, he supports research training in advanced drug delivery and formulation science. Dr. Prajapati also serves in editorial and section‑editor roles for international scientific publications, contributing to the advancement and quality of pharmaceutical research dissemination.

Dr. Devesh U. Kapoor is Professor of Pharmaceutics at Dr. Dayaram Patel Pharmacy College, Bardoli, Gujarat, affiliated with Gujarat Technological University. His academic and research expertise centers on pharmaceutics, nanodrug delivery, and modified‑release drug delivery systems. Dr. Kapoor has made extensive scholarly contributions through research and review publications, book chapters, and edited volumes with international publishers. He is actively involved in postgraduate and doctoral research supervision in advanced drug delivery technologies. His editorial experience includes serving in senior editorial roles for international journals across pharmacology, pharmaceutics, and biomedical sciences, along with regular peer‑review activity for a wide range of scientific journals. Dr. Kapoor has also secured competitive research and academic development funding and is a frequent invited speaker at national scientific meetings, workshops, and academic programs.

Dr. Jaimin R. Shah is the Founder, President, and CEO of Upsilon Innovations, based in San Diego, California, and a researcher at the University of California, San Diego. With over 14 years of experience in academia and industry, he has been a key member of multiple pharmaceutical startups and has worked on over 80 product development projects. Dr. Shah specializes in innovative drug delivery technologies, focusing on cancer, autoimmune diseases, rare diseases, and regenerative medicine. He has published numerous research papers, co-authored book chapters, and holds multiple patents. His expertise spans various dosage forms, including transdermal, topical, lipid-based systems, ophthalmics, and injectables. Dr. Shah holds a B.Pharm from Gujarat University, an M.S. in Pharmaceutics from Long Island University, and a Ph.D. in Materials Science and Engineering from UC San Diego. He is an active member of AAPS, ACS, AACR, and RSC.

Edition details

• Publisher: Academic Press
• Publication date: 2025
• Language: English
• ISBN 10: 0443366470
• ISBN 13: 9780443366475
• Binding: Paperback
• Number of pages: 388
• Editor: Prajapati